InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,187.70
(
0.13%
)
US TECH 100
17,615.60
(
0.03%
)
Dow Jones
38,884.26
(
0.08%
)
Brent Oil
82.87
(
-0.73%
)
Bitcoin
62,885.55
(
-0.44%
)
Post# of 438
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DanWebzster

Send PM Follow Ignore
Followers 10
Posts 1060
Boards Moderated 2
Alias Born 09/04/2000

DanWebzster

Member Level

Re: DanWebzster post# 257

Thursday, 07/19/2018 9:04:19 PM

Thursday, July 19, 2018 9:04:19 PM

Post# of 438
CLRB recently reported promising preliminary Ph2 data for the first patient in its trial in refractory hematologic malignancies.

These results should help CLRB enroll their goal of 80 patients.

Hematologic malignancies are expected to reach a TAM of ~86B by 2025

Cash runway would only be sufficient to get the company into Q4/18. Dilution is imminent.
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up